While we are not formally GLP-certified for in-house studies, our work is performed under a rigorous quality system aligned with advanced ISO standards, which is ideal for the exploratory and lead optimization phases of your project. Our fit-for-purpose approach allows us to provide the agility and speed needed for critical pre-TCR screening and derisking antibody therapeutics for early-stage exploratory toxicology and custom biomarker assay development designed to give you reliable, decision-grade data, fast.   This allows you to "fail fast" on non-viable candidates before making significant investments.  As you move towards the IND, our role evolves with you. We have established partnerships to facilitate a seamless bridge to a fully GLP-certified environment. This unique, two-stage approach provides the best of both worlds: the speed and direct scientific access of a boutique CRO for your early work, and a clear, managed path to the formal regulatory compliance you need for your later-stage preclinical TCR studies.

We understand that sourcing high-quality human disease tissue is often one of the biggest bottlenecks in bridging the translational gap. To solve this, we provide two clear paths;   We can manage the entire procurement process for you, leveraging our proprietary network to source high-quality, pathologist-verified sample from our tissue bank partners (FFPE and fresh frozen) or through direct internal access to a wide tissue library right here at Offspring, getting your study started without procurement headaches.  If you have your own precious cohort of samples, we act as your expert scientific custodians. Our process begins with a detailed pathology assessment to confirm cohort integrity and quality, ensuring that the data you get is reliable and robust.   Whether you use our tissue or yours, our goal is the same: to generate the most accurate, humanizing preclinical data possible.

As a responsive preclinical research partner, we are structured to avoid the bureaucratic delays common at larger CROs as our entire operational model is designed to deliver expert insights faster. While the exact timeline depends on study complexity, our standard turnaround time for most study reports is measured in weeks, not months.  We also operate on a "first signed, first served" basis, and because you have direct-access to the senior scientific partner managing your project, communication is streamlined and decisions are made quickly. This agile model significantly reduces lead times during contracting and throughout the life of the project, delivering the insights you need, faster.

Our "Pharma DNA" means we believe in building a data package that is scientifically sound and fit for its purpose. We do not rely solely on automated outputs; every study includes expert human oversight to ensure what we're seeing is true biology, not artifact. Our standard review is performed by expert scientists with more than 30 years of histopathology experience, guaranteeing decision-grade data.  We recognize that certain key studies, particularly those involving preclinical safety or complex pathology, benefit from formal certification. For these projects, we provide Board-Certified Pathologist review as an integrated service, ensuring your most critical data has the highest level of verification needed to support major investment or regulatory decisions.  This flexible, on-demand capability ensures you receive the precise level of pathologist-verified IHC scoring and expert oversight your project requires without adding unnecessary overhead to every study.

Our entire philosophy for target validation is built to move beyond simple binding assays and provide the deep, contextual data needed for a confident Go/No-Go decision. We operate under the philosophy that predicting clinical efficacy preclinically requires a holistic view of the target in its native environment: human disease tissue.  While a standard lab might confirm if a target is present, we focus on providing Context. We ask more than simply "is it there?".  We ask "is it accessible, is it active, and is it in a position to be drugged?" To do this, we employ a multi-faceted approach to target validation for clinical trials.  This systematic approach is designed to rigorously de-risk antibody therapeutics by ensuring your target is not only present, but biologically active and accessible in disease-relevant tissues.

Absolutely. In a crowded therapeutic landscape, proving your molecule is superior is critical, and we provide the platform to do just that. Our Competitive Benchmarking module is more than just a standard antibody validation for clinical trials; it's a direct interrogation of your drug's performance against its rivals.  By co-staining for your antibody and a competitor's in the same FFPE tissues in adjacent tissue sections or in a dual setting in the same tissue section, we eliminate biological variability and generate irrefutable visual evidence of performance. This side-by-side analysis, often using double-staining IHC services, allows for a direct and unambiguous comparison of specificity, binding affinity, and off-target effects in a true biological context and is ideal for demonstrating differentiated subcellular localization, proving higher specificity, or exposing potential off-target toxicity in human tissue that your competitors may have missed, giving you the confidence and data to claim 'Best-in-Class.'  The process generates the powerful, decision-grade data needed to prove superior performance and secure a competitive advantage.

Proving target engagement is the cornerstone of validating your drug's mechanism of action, and we use the most rigorous method available to do it in tissue.  While standard multiplex IHC services can show that your drug and its target are in the same neighborhood, our specialized isPLA service confirms they are physically interacting.  Using an In Situ Proximity Ligation Assay (isPLA), we generate a specific signal only when two proteins (like your drug and its target) are within nanometers of each other. This powerful technique provides unambiguous, dot-like evidence of true molecular interaction, giving you the highest level of confidence that your drug is hitting its mark in the complex environment of human tissue.  This level of specialized precision is essential for derisking antibody therapeutics, especially complex modalities like bispecifics, and is a key part of our target engagement assay development workflow.   We complement these capabilities with immunodecoration (visualize and confirm the distribution, binding, and target engagement of exogenously administered IgG antibodies at their intended sites in the tissue) from experimental models, dual autoradiography and IHC for target engagement vs biomarker detection in human tissue and directly labeled ligands and proteins for target engagement studies.

Yes, our support is designed to span the preclinical to clinical transition. For the clinical phase, we specialize in providing crucial exploratory clinical endpoints and developing effective patient stratification biomarker strategies.  Furthermore, through our strategic partnership with Flagship Biosciences, we provide a seamless bridge to CAP/CLIA-certified environments. This ensures that the exploratory assays and biomarker signatures we develop with you during the preclinical phase can be smoothly validated and deployed for regulated clinical trial sample analysis, saving you critical time and resources.  This integrated support makes us an ideal collaborative preclinical research partner, offering you a single, continuous scientific relationship from first tissue screen to first-in-human trials.

We deliver both. We believe that an image tells a story, but quantitative data drives decisions. So, while we provide stunning, high-resolution images for your review, our work doesn't stop there. We are also a premier provider of quantitative image analysis / digital pathology services. Crucially, our advanced, AI-assisted image analysis pipeline moves beyond subjective interpretation, transforming those images into objective, robust datasets. It performs sophisticated tasks like cell segmentation and signal quantification to produce objective, reproducible data. This ensures the insights you receive are not just qualitative observations but are robust statistical results ready to support critical Go/No-Go decisions and confidently predict clinical efficacy preclinically.

Absolutely. We understand that many of the most important drug targets, especially in fields like neuroscience, are not highly expressed.  Standard IHC often fails to visualize proteins with low expression levels or overcome IHC background noise, leading to false negatives. We overcome this by employing high-sensitivity signal amplification techniques.  To do this, we utilize advanced signal amplification methodologies like Tyramide Signal Amplification (TSA), which can increase detection sensitivity over 100-fold compared to standard methods. This allows us to confidently perform subcellular localization services and other analyses on even the most challenging targets, providing clear and reliable data where other labs might only find background.  We also utilize and specialized probe-based assays like RNAscope™ (an advanced ISH service) for mRNA detection. These powerful techniques allow us to visualize and quantify low-expression targets that are undetectable by other means, ensuring you don't miss a critical finding.

We treat data security with the utmost seriousness. All data processing and transfer operations are handled through secure, GDPR-compliant cloud platforms that utilize end-to-end encryption.  Upon project completion, we can provide you with secure access to all deliverables, including the high-resolution Whole Slide Images and raw analytical data. This allows your team to not only see our final analysis but also to conduct their own remote reviews of the primary source tissue images, ensuring full transparency and facilitating seamless collaboration.

Yes, absolutely. We have extensive experience managing international projects and have well-established, compliant logistics for handling biological samples from global clinical trials.  We understand that our clients operate globally, and we have built our logistics to match. As an experienced international CRO partner, we routinely manage the import of human tissue samples between the US, UK, and EU.  Our team provides full support in obtaining all necessary permits and ensuring a smooth, compliant transfer of valuable clinical samples securely, and without unnecessary delays.

Our expertise in Neuroscience is deep and broad. While we have significant experience with Amyloid-beta (like Alzheimer’s disease), alpha-synucleinopathies (like Parkinson's disease), tauopathies (like PSP, CBD) and several other proteinopathies implicated in diseases like FTD and ALS. This background gives us a unique and valuable perspective when developing validation strategies for novel neuroscience drug candidates our team has validated numerous other key targets in the field of neurodegenerative diseases.

Absolutely. Custom assay development is our core strength and the heart of what we do. The majority of our projects involve novel targets where no commercial antibody or established protocol exists.  We are structured as a specialized histopathology CRO specifically to solve this problem, building high-quality, fully customized assays from the ground up.    Our process for custom biomarker assay development is a collaborative scientific partnership. We work with you to understand your target's biology, then design a multi-stage optimization and validation strategy to create a reliable and reproducible assay.  Our scientific team excels at building robust IHC, ISH, or isPLA protocols from scratch. During our partnership, we systematically optimize every parameter, from antigen retrieval to detection systems, to create a highly specific and sensitive assay tailored to your unique target and biological question.

The first step is always to schedule a no-obligation scientific consultation with our team by clicking "Discuss Your Project" link to schedule a meeting with a senior scientific partner, not a sales representative.  This ensures you are immediately connected with the right person: a senior scientist who can speak your language and your needs.  Our initial meetings are a collaborative session designed for us to understand your unique scientific objectives. We don't offer a standardized price list because we don't offer a standardized service. Based on this discussion, we will design a custom assay development and validation plan tailored specifically to help you de-risk your therapeutic and achieve your goals.  Want to get in touch?  Reach out today to “Discuss Your Project” and see where partnering with a ‘Co-Author of Success’ can lead you.